Drug Approval | December 29, 2021
JB Chemicals and Pharmaceuticals to launch molnupiravir next month
It will be marketed under the brand name Molunamax
It will be marketed under the brand name Molunamax
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The drug will be marketed under the brand name Molnaflu
This product will be manufactured at Lupin's Goa facility in India
The Home Healthcare market is expected to be US $ 14.2 by 2025
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
Subscribe To Our Newsletter & Stay Updated
